Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.59 |
| ▸ | KDM1A | O60341 | 5/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719284 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL455245 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL799467 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL806142 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL455246 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL21501045 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL24890441 | 0.84 | KDM1A (0.50) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL799464 | 0.82 | HRH3 (0.49) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL4133964 | 0.82 | KDM1A (0.53) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL4133967 | 0.82 | KDM1A (0.53) | FFAR1KDM1AHRH3KCNH2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2598482-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | FFAR1 48/4885KDM1A 760/4885HRH3 3/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | FFAR1 43/4885KDM1A 702/4885HRH3 3/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | FFAR1 49/4885KDM1A 652/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.